Valneva SE (NASDAQ:VALN - Get Free Report) traded up 7.6% during mid-day trading on Thursday . The company traded as high as $7.24 and last traded at $7.18. 35,366 shares traded hands during trading, a decline of 34% from the average session volume of 53,530 shares. The stock had previously closed at $6.67.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a "buy" rating and set a $18.00 price objective on shares of Valneva in a research note on Friday, January 31st.
Get Our Latest Stock Analysis on Valneva
Valneva Price Performance
The stock has a 50-day simple moving average of $4.57 and a 200 day simple moving average of $5.63. The stock has a market capitalization of $568.82 million, a P/E ratio of -53.85 and a beta of 1.98. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78.
Institutional Trading of Valneva
An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC boosted its holdings in shares of Valneva SE (NASDAQ:VALN - Free Report) by 33.7% in the third quarter, according to its most recent filing with the SEC. The firm owned 118,000 shares of the company's stock after acquiring an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned 0.15% of Valneva worth $717,000 as of its most recent filing with the SEC. 11.39% of the stock is owned by hedge funds and other institutional investors.
Valneva Company Profile
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Further Reading
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
